• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Abstract Poly(ADP-ribosyl)ation is an immediate cellular repair response to DNA damage and is catalyzed primarily by poly(ADP-ribose)polymerase-1 (PARP1), which is the most abundant of the 18 different PARP isoforms and accounts for more than 90% of the catalytic activity of PARP in the cell nucleus. Upon detection of a DNA strand break, PARP1 binds to the DNA, cleaves nicotinamide adenine dinucleotide between nicotinamide and ribose and then modifies the DNA nuclear acceptor proteins by formation of a bond between the protein and the ADP-ribose residue. This generates ribosyl-ribosyl linkages that act as a signal...
Source: Cardiovascular Toxicology - July 2, 2018 Category: Cardiology Authors: Henning RJ, Bourgeois M, Harbison RD Tags: Cardiovasc Toxicol Source Type: research

Pathophysiologic role of ischemia reperfusion injury: a review
Publication date: Available online 19 June 2017 Source:Journal of Indian College of Cardiology Author(s): Vishal Kumar Vishwakarma, Prabhat Kumar Upadhyay, Jeetendra Kumar Gupta, Harlokesh Narayan Yadav Ischemic heart disease (IHD) is the major cause of morbidity and mortality all over the world. World health organization (WHO) in 2002 assumed that IHD may be the major leading cause of death by 2020. An estimated 17 million people died from cardiovascular diseases (CVS) globally. Of these deaths, 7 million people died by ischemia heart disease and 6.2 million by stroke. Ischemia is defined as an insufficient supply of the...
Source: Journal of Indian College of Cardiology - June 19, 2017 Category: Cardiology Source Type: research

Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention: The HORIZONS-AMI ECG Substudy Report Myocardial Infarction
Conclusions— In this large international study, absent STR 60 minutes after primary PCI was present in 1 in 5 patients with ST-segment–elevation myocardial infarction and was a significant independent predictor of major adverse cardiovascular events and target vessel revascularization at 3 years. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00433966
Source: Circulation: Cardiovascular Interventions - June 18, 2013 Category: Cardiology Authors: Farkouh, M. E., Reiffel, J., Dressler, O., Nikolsky, E., Parise, H., Cristea, E., Baran, D. A., Dizon, J., Merab, J. P., Lansky, A. J., Mehran, R., Stone, G. W. Tags: Electrocardiology, Catheter-based coronary interventions: stents, Acute myocardial infarction Source Type: research

Primary Percutaneous Coronary Intervention: The Deception of Delay⁎
Primary percutaneous coronary intervention (PCI) has become the predominant reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) throughout western healthcare systems. Recent estimates in the United States suggest that primary PCI is used in 85% of all STEMI cases that undergo reperfusion, with thrombolytic agents used in only 9% and the combination of thrombolytic agents with PCI in 6% (). This dramatic switch from thrombolytic therapy to primary PCI was the result of several studies conducted in the early 1990s that demonstrated the superiority of primary PCI at reducing stroke and reinfarction as ...
Source: Journal of the American College of Cardiology - April 17, 2013 Category: Cardiology Authors: Cindy L. Grines, Theodore Schreiber Tags: Acute Coronary Syndromes: Editorial Comment Source Type: research

Primary Percutaneous Coronary Intervention The Deception of Delay ⁎ ⁎
Primary percutaneous coronary intervention (PCI) has become the predominant reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) throughout western healthcare systems. Recent estimates in the United States suggest that primary PCI is used in 85% of all STEMI cases that undergo reperfusion, with thrombolytic agents used in only 9% and the combination of thrombolytic agents with PCI in 6% (1). This dramatic switch from thrombolytic therapy to primary PCI was the result of several studies conducted in the early 1990s that demonstrated the superiority of primary PCI at reducing stroke and reinfarction as...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - April 15, 2013 Category: Cardiology Source Type: research

The outcome of intra-aortic balloon pump support in acute myocardial infarction complicated by cardiogenic shock according to the type of revascularization: A comprehensive meta-analysis
Aims: Despite the recommendations of the current guidelines, scientific evidence continue to challenge the effectiveness of intra-aortic balloon pump (IABP) in acute myocardial infarction (AMI) complicated by cardiogenic shock. Moreover, 2 recent meta-analyses showed contrasting results. The aim of this study is to test the effect of IABP according to the type of therapeutic treatment of AMI: percutaneous coronary intervention (PCI), thrombolytic therapy (TT), or medical therapy without reperfusion. Articles published from January 1, 1986, to December 31, 2012, were collected and analyzed by meta-analysis.Methods and resul...
Source: American Heart Journal - March 27, 2013 Category: Cardiology Authors: Francesco Romeo, Maria Cristina Acconcia, Domenico Sergi, Alessia Romeo, Saverio Muscoli, Serafina Valente, Gian Franco Gensini, Flavia Chiarotti, Quintilio Caretta Tags: Curriculum in Cardiology Source Type: research